JPJinshu Pang

Jinshu Pang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinshu Pang has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Yang

    Department of Medical Ultrasound, the First Affiliated Hospital of Guangxi Medical University, Nanning, China

    6 shared publications
  • Yun He

    Department of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

    5 shared publications
  • Xiu-Mei Bai

    Department of Medical Ultrasound, the First Affiliated Hospital of Guangxi Medical University, Nanning, China

    4 shared publications
  • Lipeng Li

    Department of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

    3 shared publications
  • Jiamin Chen

    Department of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

    2 shared publications
  • Li Liang

    Department of Medical Ultrasound, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China

    2 shared publications

Latest Publications

  • Multi-omics analysis of the lactylation-driven microenvironment and non-invasive clinical translation in hepatocellular carcinoma

    by Xiangyu Gan, Ruizhi Gao, Dongming Xie, Xiumei Bai, Rong Wen, Mingzhao Jiang, Qinxin Li, Qiao Que, Jinbo Peng, Yuquan Wu, et al.

    Background Through integrated multi-omics strategy, this study aims to investigate the clinical value of a prognostic model derived from lysine lactylation (KLa) in hepatocellular carcinoma (HCC), thereby promoting its clinical translation. Methods The key features for constructing lactylation-associated risk model were identified across the levels of KLa, protein and transcriptomic by integrating local cohort and public HCC cohorts. Immunohistochemistry and western blotting were performed to confirm the consistency between lactylation-associated risk and KLa modification level. Clinical and biological significance of lactylation-associated risk stratification was further characterized leveraging local cohort with public HCC cohort and single-cell sequencing. Finally, we explored the potential of ultrasound-based radiomics for non-invasive prediction of lactylation-associated risk. Results Lactylation-associated risk model effectively stratified HCC patients based on recurrence-free survival and identified individuals with early postoperative recurrence. High-risk patients demonstrated elevated KLa modification level and clinical characteristics indicative of poor prognosis: microvascular invasion, tumor thrombus, high Ki-67, advanced TNM and BCLC stages. At single-cell resolution, the predominantly immunosuppressive tumor immune microenvironment and KLa-driven proliferative tumor phenotype in high-risk patients elucidate the underlying biological mechanisms of HCC progression. The integration of ultrasound-based radiomics and clinical features demonstrated superior potential for lactylation-associated risk non-invasive prediction compared to single clinical model. Conclusion Lactylation-associated risk model not only provides an effective assessment of recurrence risk in HCC patients but also mirrors the intratumoral KLa modification level, holding significant clinical and tumor biological relevance. Furthermore, the joint model integrating ultrasound-based radiomics and clinical features demonstrates potential for non-invasive prediction of lactylation-associated risk. Graphical abstract


  • Open Access

    Ferroptosis-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma: A multi-cohort retrospective study

    by Lipeng Li, Jinshu Pang, Jiamin Chen, Yunjing Pan, Li Liang, Xiumei Bai, Yun He, Hong Yang

    Hepatocellular carcinoma (HCC), characterized by elevated incidence and mortality rates, has a considerable economic impact worldwide. The function of ferroptosis within the tumor microenvironment of HCC is crucial, and the specific contributions of ferroptosis-related genes (FRGs) are yet to be fully explored. FRG expression levels and relevant clinical data were sourced from The Cancer Genome Atlas. Two distinct ferroptosis-related subtypes were identified in liver cancer and their interrelationships were comprehensively examined. Using Cox regression and least absolute shrinkage and selection operator regression analysis, we created a predictive model based on FRGs to forecast overall survival and assess the potential benefits of immunotherapy in patients with HCC. Quantitative reverse transcription-polymerase chain reaction and IHC assays were conducted on clinical HCC specimens to validate the key FRGs. Significant differences in gene mutations, immune reactions, and prognostic outcomes were observed between the 2 distinct ferroptosis-related subtypes. An eight-gene signature consisting of SLC1A5, KIF20A, SLC7A11, CARS1, MYCN, PRDX6, GPX4, and KLF2 was established as a predictive model for liver cancer and was validated against data from GSE76427 and the International Cancer Genome Consortium cohorts. According to the FRG model, individuals classified as low-risk exhibited more favorable survival prospects compared to their high-risk counterparts ( P < .05). Overall, our investigation highlights the promise of FRGs as prognostic biomarkers and immunotherapy response in HCC, providing a novel approach for personalized patient management.

  • Development of a model combining CEUS LI-RADS and clinical features for predicting glypican-3 expression in hepatocellular carcinoma

    by Fen Huang, Jinshu Pang, Yuquan Wu, Yueting Sun, Rong Wen, Xiumei Bai, Wanxian Nong, Ruizhi Gao, Yun He, Cuiling Li, et al.

    Objective To establish a predictive model incorporating clinical features and contrast-enhanced ultrasound (CEUS) liver Imaging Reporting and Data System (LI-RADS) for predicting glypican-3 (GPC3) expression in hepatocellular carcinoma (HCC). Methods A total of 142 HCC patients between January 2020 to June 2021 in our institution were retrospectively analyzed. All patients underwent CEUS before surgery, and the reference standard was immunohistochemical analysis of surgical specimen. The clinical features, conventional ultrasound features, and CEUS LI-RADS features of patients in the GPC3-positive and GPC3-negative groups were evaluated and compared. The variables screened by multivariable logistic regression were used to develop a model for predicting GPC3 expression and the predictive precision and clinical utility of the model was evaluated using receiver operating characteristic analysis and decision curve analysis. Results Among the 142 HCC patients, 96 (67.6%) were classified as LR-4/5 lesions, 46 (32.4%) were classified as LR-M lesions, 101 (71.1%) were GPC3-positive and 41 (28.9%) were negative. Multivariable logistic regression analysis showed that younger age (OR = 0.947; 95% CI: 0.910–0.985; p = 0.007), alpha-fetoprotein > 400 ng/ml (OR = 5.202; 95% CI: 1.808–14.966; p = 0.002) and LI-RADS M (OR = 2.822; 95% CI: 1.101–7.236; p = 0.031) was independent risk factors for GPC3-positive HCC. The model combining clinical features and LI-RADS categories showed better performance than single variable, with AUC of 0.759 (p < 0.05). The nomogram and decision curves revealed substantial clinical benefit of the prediction model in predicting GPC3 expression. Conclusion The combined model incorporating clinical features and CEUS LI-RADS achieved a satisfactory performance for predicting GPC3 expression in HCC patients. Graphical Abstract


  • Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma

    by Li Liang, Jin-Shu Pang, Rui-Zhi Gao, Qiao Que, Yu-Quan Wu, Jin-Bo Peng, Xiu-Mei Bai, Qiong Qin, Quan-Quan Tang, Li-Peng Li, et al.

    Purpose We aimed to develop and validate a combined model integrating radiomic features derived from Contrast-Enhanced Ultrasound (CEUS) images and clinical parameters for preoperative prediction of CK19-positive status in hepatocellular carcinoma (HCC). Methods A total of 434 patients who underwent CEUS and surgical resection from January 2020 to December 2023 were included. Patients were randomly divided into a training cohort (n = 304) and a validation cohort (n = 130). Radiomic features were extracted from multiphase CEUS images, including two-dimensional ultrasound (US), arterial, portal venous, and delayed phases, and combined to derive a Radscore model. Subsequently, a Combined Model was constructed using the Radscore and clinical parameters. Model performance was assessed using calibration, discrimination, and clinical utility. Results Multivariate logistic regression analysis identified Radscore (OR = 10.054, 95% CI: 5.931–19.120, p < 0.001) and AFP levels > 200 ng/mL (OR = 5.027, 95% CI: 2.089–12.784, p < 0.001) as significant predictors in the combined model. The AUC (Area Under the Curve) for the Combined Model was 0.954 in the training cohort and 0.927 in the validation cohort, compared to 0.939 and 0.917 for the Radscore Model alone. Calibration curves demonstrated strong concordance between predicted and actual outcomes. Decision curve analysis (DCA) showed that both the Radscore Model and the Combined Model exhibited good net benefits across a wide range of threshold values in both the training and validation cohorts. Conclusion The Radscore based on CEUS, combined with the serum markers AFP > 200 ng/L to construct a Combined Model, shows good predictive performance for CK19 + hepatocellular carcinoma (HCC).


  • Overexpression of PLK1 Molecule Following Incomplete Thermal Ablation Promotes the Proliferation and Invasion of Residual Hepatocellular Carcinoma

    by Tong Kang, Jiamin Chen, Weijun Wan, Jinshu Pang, Rong Wen, Xiumei Bai, Lipeng Li, Yunjing Pan, Yun He, Hong Yang

    TAT, a widely used treatment for HCC, can exacerbate the progression of residual HCC. The present study investigated the mechanism of action of PLK1 following ITA of HCC. The PLK1 levels in HCC were determined using qRT-PCR from clinical patient samples, IHC from tissue microarray, and data from globally high-throughput data and microarrays. The PLK1 levels and their effect on the biological phenotype of heat-stress HCC cells were evaluated through in vitro experiments. We detected PLK1 abnormal expression in HCC models of nude mice subjected to ITA. We detected the effects of different PLK1 expression levels on EMT pathway proteins. PLK1 exhibited an overexpression in HCC tissues with an SMD of 1.19 (3414 HCC and 3036 non-HCC tissues were included), distinguishing HCC from non-HCC effectively (AUC = 0.9). The qRT-PCR data from clinical HCC patient samples and IHC from HCC tissue microarray results also indicated an overexpressed level. In the incomplete ablation models, an increased PLK1 expression was found in both heat-stress cells and subcutaneous tumors. The upregulation of PLK1 following ITA was found to enhance the malignancy of HCC and exacerbate the proliferation, migration, and invasion of residual HCC cells, whereas PLK1 knockdown suppressed the biological malignancy of HCC cells. Meanwhile, PLK1 has different regulatory effects on various EMT pathway proteins. PLK1 promotes the progression of residual HCC by activating EMT pathway after ITA, which might provide a novel idea for the treatment and prognosis of residual HCC.


  • Open Access

    Exploring the impact of insufficient thermal ablation on hepatocellular carcinoma: NDST2 overexpression mechanism and its role in facilitating growth and invasion of residual cancer cells

    by Weijun Wan, Danxia Guo, Tong Kang, Jinshu Pang, Yunjing Pan, Jiamin Chen, Wei Liao, Yuji Chen, Peng Lin, Lipeng Li, et al.

    Incomplete thermal ablation (ITA) fosters the malignancy of residual cells in Hepatocellular carcinoma (HCC) with unclear mechanisms now. This study aims to investigate the expression changes of NDST2 following ITA of HCC and its impact on residual cancer cells. An in vitro model of heat stress-induced liver cancer was constructed to measure the expression of NDST2 using Quantitative Real-Time PCR and Western blotting experiments. The sequencing data from nude mice were used for validation. The clinical significance of NDST2 in HCC was evaluated by integrating datasets. Gene ontology and pathway analysis were conducted to explore the potential signaling pathways regulated by NDST2. Additionally, NDST2 was knocked down in heat stress-induced HCC cells, and the effects of NDST2 on these cells were verified using Cell Counting Kit-8 assays, scratch assays, and Transwell assays. NDST2 expression levels are elevated in HCC, leading to a decrease in overall survival rates of HCC patients. Upregulation of immune checkpoint levels in high NDST2-expressing HCC may contribute to immune evasion by liver cancer cells. Additionally, the low mutation rate of NDST2 in HCC suggests a relatively stable expression of NDST2 in this disease. Importantly, animal and cell models treated with ITA demonstrate upregulated expression of NDST2. Knockdown of NDST2 in heat stress-induced liver cancer cells results in growth inhibition associated with gene downregulation. The upregulation of NDST2 can accelerate the progression of residual HCC after ITA, suggesting a potential role for NDST2 in the therapeutic efficacy and prognosis of residual HCC.


  • Open Access

    Downregulation of MicroRNA-1 and Its Potential Molecular Mechanism in Nasopharyngeal Cancer: An Investigation Combined with In Silico and In-House Immunohistochemistry Validation

    by Jia-Ying Wen, Li-Ting Qin, Gang Chen, He-Qing Huang, Ming-Jun Shen, Jin-Shu Pang, Yu-Xing Tang, Wei Lu, Ren-Sheng Wang, Jia-Yuan Luo

    Background. This study was aimed at elucidating the molecular biological mechanisms of microRNA-1 (miR-1) in nasopharyngeal carcinoma (NPC). Method. In this study, we performed a pooled analysis of miR-1 expression data derived from public databases, such as GEO, ArrayExpress, TCGA, and GTEx. The miRWalk 2.0 database, combined with the mRNA microarray datasets, was used to screen the target genes, and the genes were then subjected to Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment analysis using the DAVID 6.8 database. We then used the STRING 11.0 database and Cytoscape 3.80 software to construct a protein-protein interaction (PPI) network for screening hub genes. Immunohistochemistry (IHC) was further used to validate the expression of hub genes. Finally, potential therapeutic agents for NPC were screened by the Connectivity Map (cMap) database. Results. Pooled analysis showed that miR-1 expression was significantly decreased in NPC ( ; ). The summary receiver operating characteristic curve suggested that miR-1 had a good ability to distinguish cancerous tissues from noncancerous tissues ( ). The results of GO analysis focused on mitotic nuclear division, DNA replication, cell division, cell adhesion, extracellular space, kinesin complex, and extracellular matrix (ECM) structural constituent. The KEGG analysis suggested that the target genes played a role in key signaling pathways, such as cell cycle, focal adhesion, cytokine-cytokine receptor interaction, ECM-receptor interaction, and PI3K/Akt signaling pathway. The PPI network suggested that cyclin-dependent kinase 1 (CDK1) was the hub gene, and the CDK1 protein was subsequently confirmed to be significantly upregulated in NPC tissues by IHC. Finally, potential therapeutic drugs, such as masitinib, were obtained by the cMap database. Conclusion. miR-1 may play a vital part in NPC tumorigenesis and progression by regulating focal adhesion kinase to participate in cell mitosis, regulating ECM degradation, and affecting the PI3K/Akt signaling pathway. miR-1 has the potential to be a therapeutic target for NPC.


  • Open Access

    A Comprehensive Evaluation of miR-144-3p Expression and Its Targets in Laryngeal Squamous Cell Carcinoma

    by Bin-Yu Mo, Jin-Shu Pang, Wen-Bin Dai, Ya-Si Su, Wei Jiang, Su-Ning Huang

    Laryngeal squamous cell carcinoma (LSCC) is an aggressive type of head and neck squamous cell carcinoma (HNSCC) with a relatively high rate of morbidity and mortality. An altered miR-144-3p level in LSCC with a small number of patients has been previously reported. However, the clinical implication of miR-144-3p and its involved mechanism underlying this disease is not clearly elucidated. In this work, we aimed to confirm the expression of miR-144-3p with larger samples and also to identify target genes for the investigation of the underlying mechanism of miR-144-3p in LSCC. The levels of miR-144-3p were downregulated in 155 samples of LSCC tissues as compared to 26 non-LSCC samples (SMD: -0.78; 95% confidence interval (CI): -1.23, -0.32). The AUC of 0.90 in the summarized ROC curve also indicated a potential ability to differentiate LSCC from non-LSCC tissues, with a sensitivity of 0.78 and a specificity of 0.88. With respect to the molecular mechanism, we predicted the potential targets from online-based prediction, peer-reviewed publications, and RNA-seq and microarray data. In particular, the genes influenced by transfection with miR-144-3p in the LSCC FaDu cell line were collected from the microarray GSE56243. Lastly, 12 novel targets for miR-144-3p in LSCC were obtained by different algorithms. In conclusion, our study confirmed the loss or downregulation of miR-144-3p in LSCC, which might contribute to the LSCC tumorigenesis and progression via regulation of the 12 novel targets, such as IL24, ITGA6, and CEP55. In the future, further investigations are required to validate the present results.